In an April 2 letter, a group of over 200 stakeholders urged the Drug Enforcement Administration (DEA) to release a revised proposed rule that would “permit and regulate the prescribing of controlled substances through…
Continue Reading
With current pandemic-era flexibilities for telemedicine set to expire at the end of 2024, several telehealth groups and major health systems are calling on the U.S. Drug Enforcement Administration to work faster in crafting…
Continue Reading
By Anuja Vaidya
March 06, 2024 – The United States Attorney’s Office for the Central District of California has sentenced a former physician to 37 months in federal prison for illegally prescribing medications, including opioid-based drugs,…
Continue Reading
This month, the U.S. Department of Health and Human Services (HHS) and the Substance Abuse and Mental Health Services Administration (SAMHSA) took steps to expand access to opioid use disorder treatment through its new…
Continue Reading
Two bills in U.S. Congress this year are expected to boost e-prescriptions. This article explains the complexities that makes it so hard to implement electronic prescribing for controlled substances (EPCS), summarizes the intended impacts…
Continue Reading
Over the last several years, the opioid crisis has become a household discussion as government agencies have increased efforts to build awareness of and prevent further deaths from controlled substance abuse. As part of…
Continue Reading
When the Drug Enforcement Administration (DEA) released its proposed rule that would remove some of the Covid-19 telehealth flexibilities for the prescribing of controlled substances, it caused an uproar from telehealth companies and advocates….
Continue Reading
By Anuja Vaidya
November 06, 2023 – A bipartisan group of four senators reintroduced legislation that would eliminate barriers to the virtual prescription of medication for opioid use disorder (OUD).
Called the Telehealth Response for E-prescribing Addiction…
Continue Reading
The DEA has extended remote prescribing of controlled substances until the end of 2024, granting a second extension to consider new regulations. This move eliminates the proposed rule requiring in-person visits for controlled medication…
Continue Reading
At the Drug Enforcement Agency Drug Diversion Division listening sessions earlier this month, DEA Administrator Anne Milgram said the agency would hold a second comment period on its March NPRM in the months ahead.WHY…
Continue Reading
